# A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

> **NCT06140836** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 190 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Repotrectinib
- **DRUG:** Crizotinib

## Key facts

- **NCT ID:** NCT06140836
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-21
- **Primary completion:** 2026-03-13
- **Final completion:** 2027-03-15
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06140836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06140836, "A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06140836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*